<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00708773</url>
  </required_header>
  <id_info>
    <org_study_id>13934B</org_study_id>
    <nct_id>NCT00708773</nct_id>
  </id_info>
  <brief_title>Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Genotype-Directed Dose-Escalation Study of Irinotecan (NSC616348, CPT-11, Camptosar) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Describe the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of irinotecan in&#xD;
      cancer patients with advanced solid tumors with UGT1A1 6/6 and 6/7 genotypes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>dose-limiting toxicity</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-tumor response</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>90 minute IV infusion once every 3 weeks.&#xD;
Dose will be based on sex and genotype determination.</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>CPT-11</other_name>
    <other_name>Camptosar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor or lymphoma that is appropriate for treatment&#xD;
             with irinotecan.&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy of greater than 12 weeks.&#xD;
&#xD;
          -  Normal organ and marrow function as defined below:&#xD;
&#xD;
               -  leukocytes ≥ 3,000/μl&#xD;
&#xD;
               -  absolute neutrophil count ≥ 1,500/μl&#xD;
&#xD;
               -  platelets ≥ 100,000/μl&#xD;
&#xD;
               -  total bilirubin within normal institutional limits&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional ULN (≤5 X ULN in patients with hepatic&#xD;
                  metastases)&#xD;
&#xD;
               -  creatinine within normal institutional limits OR&#xD;
&#xD;
               -  glomerular filtration rate ≥50 ml/min/1.73 m2 for patients with creatinine levels&#xD;
                  above institutional normal as calculated by the modified MDRD equation&#xD;
                  recommended by the National Kidney Disease Education Program&#xD;
&#xD;
          -  Measurable or assessable disease.&#xD;
&#xD;
          -  Able to understand and the willing to sign a written informed consent document.&#xD;
&#xD;
          -  Women of child-bearing potential and men and their partners must agree to use adequate&#xD;
             contraception (hormonal or barrier method of birth control) prior to study entry and&#xD;
             for the duration of study participation.&#xD;
&#xD;
          -  Patients with UGT1A1 genotype 6/6, 6/7, and 7/7. Patients with either one or two of&#xD;
             the rare alleles (i.e., 5 allele and 8 allele), and carriers of the *6 allele will not&#xD;
             be enrolled in the study. Patients will have blood drawn for genotyping upon signing&#xD;
             the informed consent form for this study.&#xD;
&#xD;
          -  Patients taking any statin therapy should interrupt the dosing of the statin for the 3&#xD;
             days before and after the administration of irinotecan at each cycle&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Biologic therapy, chemotherapy, radiotherapy, or investigational agent within 4 weeks&#xD;
             (6 weeks for nitrosoureas or mitomycin C) prior to entering the study.&#xD;
&#xD;
          -  Cannot be receiving any other investigational agents.&#xD;
&#xD;
          -  Use of colony growth factor within 3 week prior to study entry.&#xD;
&#xD;
          -  Post-transplant patients, as they may be subject to severe neutropenia.&#xD;
&#xD;
          -  Uncontrolled brain metastases. Patients with brain metastases must have stable&#xD;
             neurologic status off of steroids and anticonvulsants for at least 4 weeks and must be&#xD;
             without neurologic dysfunction that would confound the evaluation of neurologic and&#xD;
             other adverse events.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Pregnant women are excluded from this study because irinotecan is an agent with the&#xD;
             potential for teratogenic or abortifacient effects. Breastfeeding should be stopped.&#xD;
&#xD;
          -  HIV-positive patients, as patients with immune deficiency are at increased risk of&#xD;
             lethal infections when treated with marrow-suppressive therapy.&#xD;
&#xD;
          -  History of inflammatory bowel disease requiring therapy or patients with chronic&#xD;
             diarrhea syndromes or paralytic ileus.&#xD;
&#xD;
          -  Patients who have undergone a major surgical procedure, open biopsy or significant&#xD;
             traumatic injury within 28 days prior to start of therapy cannot participate.&#xD;
&#xD;
          -  Patients with prior pelvic irradiation cannot participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federico Innocenti, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>June 27, 2008</study_first_submitted>
  <study_first_submitted_qc>July 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2008</study_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

